Cocrystal pharma reports favorable preliminary data from phase 1 initial cohorts with cc-42344, a novel, broad-spectrum influenza a antiviral

Cc-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile
COCP Ratings Summary
COCP Quant Ranking